<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04356105</url>
  </required_header>
  <id_info>
    <org_study_id>12020</org_study_id>
    <nct_id>NCT04356105</nct_id>
  </id_info>
  <brief_title>Protocols of IVF/ICSI in Poor Responders</brief_title>
  <official_title>Minimal Stimulation in a Combined Letrozole Antagonist Protocol Versus Microflare Protocol in Poor Responders Undergoing Invitrofertilization/ Intracytoplasmic Sperm Injection; Randomized Parallel Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing two ovarian induction protocols in poor responders in IVF/ICSI cycles
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The two groups of poor responders are randomized into either; a minimal dose stimulation
      protocol involving letrozole, recombinant FSH and GnRH antagonist versus a microflare
      conventional protocol with OCP, GnRH agonist and high dose recombinant FSH, in their IVF/ICSI
      cycles, primary outcome will be the number of oocytes retrieved.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Two groups of poor ovarian responders to be given two different induction protocols at the same time duration of the study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of oocytes retrieved</measure>
    <time_frame>10 to 14 days</time_frame>
    <description>the number of oocytes collected from each participants in the two groups on the day of ovum pickup</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of MII oocytes retrieved</measure>
    <time_frame>10 to 14 days</time_frame>
    <description>The mature oocytes colloected on the day of ovum pickup</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of fertilized oocytes</measure>
    <time_frame>2 days</time_frame>
    <description>Number of oocytes fertilized</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of embryos transferred</measure>
    <time_frame>Day 3 after ovum pickup</time_frame>
    <description>Number of embryos transferred in the induction cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of embryos cryopreserved</measure>
    <time_frame>Day 3 after ovum pickup</time_frame>
    <description>Any surplus good quality embryos available for cryopreservation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemical pregnancy rate</measure>
    <time_frame>14 days after embryo ransfer</time_frame>
    <description>Positive pregnancy test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>5 to 7 weeks after embryo transfer</time_frame>
    <description>Positive heart beat</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early miscarriage rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>loss of pregnancy before 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>12 weeks</time_frame>
    <description>pregnancy beyond 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live birth rate</measure>
    <time_frame>28 to 40 weeks</time_frame>
    <description>Delivery beyond 28 weeks</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cancellation rate</measure>
    <time_frame>10 to 14 days</time_frame>
    <description>Number of cycles not reaching ovum pickup</description>
  </other_outcome>
  <other_outcome>
    <measure>Total dose of recombinant FSH</measure>
    <time_frame>10 to 14 days</time_frame>
    <description>The mean total dose of recombinant FSH used in the cycle of treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>Minimal Stimulation Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Minimal dose stimulation ovarian induction protocol given to poor responders, involving letrozole, low dose recombinant FSH and GnRH antagonist</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Microflare Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Microflare ovarian induction protocol given to poor responders, involving OCP, GnRH agonist, high dose recombinant FSH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Minimal stimulation protocol</intervention_name>
    <description>Letrozole, Recombinant FSH, GnRH antagonist</description>
    <arm_group_label>Minimal Stimulation Group</arm_group_label>
    <other_name>Ovarian induction protocol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Microflare protocol</intervention_name>
    <description>OCP, GnRH agonist, Recombinant FSH</description>
    <arm_group_label>Microflare Group</arm_group_label>
    <other_name>Ovarian induction protocol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>IVF/ICSI cycle</intervention_name>
    <description>Involving ovum pickup and embryo transfer</description>
    <arm_group_label>Microflare Group</arm_group_label>
    <arm_group_label>Minimal Stimulation Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1- More than 1 year of infertility 2 - Poor ovarian responder according to the Bologna
        criteria:

          1. Advanced maternal age

          2. Previous poor ovarian response

          3. Abnormal tests of ovarian reserve (AFC &lt; 5-7, AMH &lt;0.5-1.1 ng/ml)

        Exclusion Criteria:

          1. Age &gt; 43 years

          2. baseline FSH &gt;15 mIU/ml

          3. Previous ovarian surgery

          4. Ovarian endometrioma

          5. Uterine anomaly or myoma

          6. Any medical disorder

          7. Any hormonal disorder eg. hyperprolactinemia

          8. BMI &gt; 30 kg/m2

          9. Severe male factor
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>43 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarwat Ahwany, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yasmin A Bassiouny, MD</last_name>
    <phone>+201001720751</phone>
    <email>yasminbassiouny@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>IVF centre, Obstetrics and Gynaecology Department, Cairo University Hospitals (Kasr EL Aini)</name>
      <address>
        <city>Cairo</city>
        <zip>12311</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmin A Bassiouny, MD</last_name>
      <phone>+201001720751</phone>
      <email>yasminbassiouny@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmin A Bassiouny, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 18, 2020</study_first_submitted>
  <study_first_submitted_qc>April 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2020</study_first_posted>
  <last_update_submitted>June 2, 2020</last_update_submitted>
  <last_update_submitted_qc>June 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Yasmin Ahmed Bassiouny</investigator_full_name>
    <investigator_title>Assisstant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

